Ipilimumab  (Synonyms: MDX-010; BMS-734016)

Ipilimumab is a fully human monoclonal antibody IgG1κ that blocks the inhibitory receptor cytotoxic T lymphocyte antigen 4 (CTLA-4) on T cells. Ipilimumab can be used in unresectable or metastatic melanoma (MM) studies^[1].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

Ipilimumab inhibits CTLA-4, allowing the T cell immune response to be reactivated against tumor cells. Ipilimumab can promote antitumor activity as a single agent or in combination with cytokines, chemotherapy, or vaccines^[1].
Ipilimumab (0, 5 or 50 μg/ mL, 6 days) alone can enhance IL-2 production and in combination with nivolumab stimulate higher IL-2 release in peripheral blood mononuclear cells (PBMC). And the combination of ipilimumab and nivolumab treatment synergistically enhances effector and memory T-cell responses^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Ipilimumab (i.v., 3 or 10 mg/kg, once a week for 4 weeks) combination with nivolumab (10 or 50 mg/kg) results in gastrointestinal inflammation in crab-eating monkeys and is associated with reduced albumin, increases globulin and increases neutrophil and eosinophil counts and mononuclear inflammation of the large intestine. Recurrent diarrhoea is demonstrated in the high-dose group, which also has visible degranulation of glandular blast cells in the pancreas^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

145380.00

477202-00-9

Liquid

Colorless to light yellow

[Ipilimumab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Ipilimumab has a significant CDC effect on CHOK1-human CTLA4 cells in a dose-dependent manner.The EC₅₀ for this effect is 604 ng/mL.

• [1]. Movva S, et al. The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab (MDX-010), a novel treatment strategy in cancer management. Expert Opin Biol Ther. 2009 Feb;9(2):231-41.  [Content Brief]

  [2]. Mark J Selby, et al. Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology. PLoS One. 2016 Sep 9;11(9):e0161779.  [Content Brief]